ECM Transactions

• Folangsi Co., Ltd (2499.HK) in its HK$155 million (approximately US$20.15 million) IPO and listing on the Hong Kong Stock Exchange
• Beauty Farm Medical and Health Industry Inc. in its approximately US$100 million IPO and listing on the Hong Kong Stock Exchange
• Cryofocus Medtech (Shanghai) Co., Ltd. in its IPO and listing on the Hong Kong Stock Exchange
• OrbusNeich Medical Group in its US$62 million IPO and listing on the Hong Kong Stock Exchange
• Jenscare Scientific Co., Ltd. in its IPO and listing on the Hong Kong Stock Exchange
• RemeGen in its approximately US$412 million A-share IPO and listing on the Sci-Tech Innovation Board of the Shanghai Stock Exchange
• Shanghai Bio-heart Biological Technology Co., Ltd. in its US$65.3 million IPO and listing on the Hong Kong Stock Exchange
• OrbusNeich Medical Group in its US$200 million Series A and A-2 Fundraising Rounds
• Goldman Sachs (Asia) L.L.C. and China International Capital Corporation Hong Kong Securities Limited and other underwriters in the US$145 million IPO and listing of Shanghai HeartCare Medical Technology Corporation Limited on the Hong Kong Stock Exchange
• Brii Biosciences Limited in its US$318 million IPO and listing on the Hong Kong Stock Exchange
• Keymed Biosciences Inc. in its US$398 million IPO and listing on the Hong Kong Stock Exchange
• Fortune Financial Capital as sole sponsor, Fortune Securities, CICC as joint global coordinators and other underwriters in the US$56.8 million primary listing of Zero2IPO Holdings Inc. on the Hong Kong Stock Exchange
• JACOBIO Pharmaceuticals Group Co., Ltd. in its US$174 million IPO and listing on the Hong Kong Stock Exchange
• RemeGen Co., Ltd. in its US$515 million IPO and listing on the Hong Kong Stock Exchange
• Honliv Healthcare Management Group Company Limited in its US$41.3 million IPO and listing on the Hong Kong Stock Exchange
• Peijia Medical Limited in its US$343 million IPO and listing on the Hong Kong Stock Exchange
• Shanghai Kindly Medical Instrument Co., Ltd., in its US$106 million IPO and listing on the Hong Kong Stock Exchange
• Pharmaron in its approximately US$588 million dual primary listing and H share offering in Hong Kong
• China Securities (International) Corporate Finance Company Limited, as the sole sponsor and lead underwriter, in the US$133 million IPO of mobile game publisher FingerTango Inc.(6860.HK) on the Hong Kong Stock Exchange
• China Securities (International) Corporate Finance Company Limited, as the sole sponsor and lead underwriter, in the US$40 million IPO of mobile game publisher Digital Hollywood Interactive Limited (2022.HK) on the Hong Kong Stock Exchange
• Dexin China Holdings Company Limited (2019.HK) in its US$190 million IPO and listing on the Hong Kong Stock Exchange
• Shanghai Haohai Biological (6826.HK) in its US$300 million IPO and listing on the Hong Kong Stock Exchange
• Phoenix Healthcare Group Co. Ltd. in its HK$1.5 billion (US$190 million) IPO on the Main Board of the Hong Kong Stock Exchange
• Hengxing Gold Holding Company Limited in its HK$330 million (US$42.3 million) IPO on the Main Board of the Hong Kong Stock Exchange
• Representing a Beijing based hospital group in its proposed listing on the Main Board of the Hong Kong Stock Exchange

Corporate and M&A Transactions

• RemeGen in its exclusive worldwide license agreement with Seagen Inc.
• LifeTech Scientific Corporation in its issuance of convertible notes valued at HK$2 billion (US$281 million) as part of the strategic investment by Medtronic, Inc. (a Fortune 500 Company)
• a Korea based entertainment group in the acquisition of the entire equity interest of a Hong Kong private company. The private company is principally engaged in the entertainment business
• a PRC based mining company in the US$85 million pre-IPO investment by Deutsche Bank AG, Hong Kong Branch
• a shareholder of a NASDAQ-listed company engaging in the business of producing and selling a wide variety of fruit products in its first round of financing through subscription of exchange bonds and preferred shares. The investors include sovereign funds and a state-owned bank

DCM Transactions

• China Eastern Airline in connection with its “dim sum” bond offering of RMB2.2 billion 3.875% guaranteed bonds and a tap issue of RMB800 million 4.8% guaranteed bonds